Navigation

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide

Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma

Status: History
Expected date of issue: June 2007
Process: MTA
Topic area:
  • Cancer
  • Central nervous system
 

NICE project team

Executive Lead: Andrea Sutcliffe
Technical Lead: Louise Longworth
Communications manager: Sarita Tamber
Project manager: Alana Miller
Assessment Group / Evidence Review Group: Peninsula Technology Assessment Group
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: December 2004
Information meeting with consultees: 06 April 2005
Closing date for invited submissions / evidence submission: 10 June 2005
Final scope published: February 2005
1st appraisal committee meeting: 23 November 2005
2nd appraisal committee meeting: 28 February 2006
3rd appraisal committee meeting: 22 November 2006
4th appraisal committee meeting: 21 February 2007
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Link Pharmaceuticals Ltd (carmustine implants)
  • Schering-Plough Ltd (temozolomide)

Patient / Carer Groups

  • Brain Tumour UK (formerly UK Brain Tumour Society)
  • Brain and Spine Foundation
  • Cancerbackup
  • Cancer Research UK
  • Samantha Dickinson Research Trust
  • Tenovus Cancer Information Centre

Professional Groups

  • Association of British Neurologists
  • British Psychosocial Oncology Society
  • Cancer Networks Pharmacists Forum (formerly British Oncology Pharmacy Association)
  • National Hospital for Neurology & Neurosurgery (Institute of Neurology, UCL)
  • Royal College of Nursing
  • Royal College of Physicians' Medical Oncology Joint Special Committee
  • Society of British Neurological Surgeons

Others

  • Department of Health
  • Gedling PCT
  • Welsh Assembly Government

General

  • British National Formulary
  • National Public Health Service for Wales
  • NHS Quality Improvement Scotland
  • Medical and Healthcare Products regulatory Agency

Comparator Manufacturers

  • Briston-Myers Squibb Pharmaceuticals Ltd (carmustine)
  • Cambridge Laboratories (procarbazine)
  • Mayne Pharma plc (vincristine)
  • Medac UK (Lomustine)

Assessment Team

  • National Coordinating Centre for Health Technology Assessment
  • Peninsula Technology Assessment Group, University of Essex
  • Associated Guideline Groups
  • National Collaborating Centre for Cancer
  • Associated Public Health Groups

None

  • Research Groups
  • Institute of Cancer Research
  • MRC Clinical Trials Unit

Top


 

Project history

Date Update
16 August 2004 Topic summary published.
24 August 2004 Title changed: Technical Lead and Communications Manager named.
25 January 2005 Project manager updated.
16 February 2005 Title of appraisal updated.
23 February 2005 Final scope, final matrix, summary of comments on the draft scope and response to comments on the provisional matrix published.
17 May 2005 Provisional schedule updated.
9 June 2005 Provisional schedule updated.
23 January 2006 Consultees and commentators updated.
15 May 2006 The reanalysis performed by the Assessment Group was released to consultees and commentators. And the appeal period for this appraisal has been extended to 31 May 2006.
30 August 2006 The appeal hearing, scheduled for 18 September 2006 is cancelled. A miscalculation in the glioma model developed by the assessment group has been discovered. In these circumstances, the Institute has decided to ask the Appraisal Committee to consider revised analysis. The revised analysis will be circulated to consultees and commentators in advance of the committee meeting. Comments on the revised analysis will be presented to the committee to inform their deliberations. The date of the next Committee meeting will be 22 November 2006.
14 September 2006 Schedule updated.
20 December 2006 Schedule updated.
14 February 2007 Stakeholder list updated.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.